Morgan Stanley initiated coverage on Arrowhead with a new price target
$ARWR
Biotechnology: Pharmaceutical Preparations
Health Care
Morgan Stanley initiated coverage of Arrowhead with a rating of Equal-Weight and set a new price target of $41.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2024 | $31.00 | Neutral | Goldman |
| 12/4/2023 | $29.00 | Buy | BofA Securities |
| 9/19/2023 | $33.00 | Neutral | Citigroup |
| 7/21/2023 | Outperform | TD Cowen | |
| 5/12/2023 | $40.00 | Outperform → Market Perform | SVB Securities |
| 4/26/2023 | $80.00 | Outperform | SMBC Nikko |
| 4/12/2023 | $21.00 → $35.00 | Market Perform → Outperform | SVB Securities |
| 3/21/2023 | $27.00 | Mkt Perform | Bernstein |
10-Q - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)
SCHEDULE 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)
Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00
BofA Securities initiated coverage of Arrowhead with a rating of Buy and set a new price target of $29.00
Citigroup initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $33.00
- Conference Call and Webcast Today, February 5, 2026, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025. The Company is hosting a conference call today, February 5, 2026, at 4:30 p.m. ET to discuss the results. "We had another quarter of strong execution across all areas of our business and we think Arrowhead is extremely well positioned to build on this progress throughout 2026 and beyond," said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. "In fact, the recent months have included some of the more significant achievements in our Company's history. We received regulat
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec
- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3, and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in hyperlipidemic nonhuman primates - Study initiation further highlights Arrowhead's innovation and leadership in the delivery of siRNA and the versatility of Arrowhead's proprietary TRiM™ technology Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference (RNAi) th
NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600: S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.
NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call. For analysts that wish to participate in the conference call, please register at https://register-conf.media-server.com/register/BIf75928b390fb452f963ab43a18d60220. Once registered, you
- Conference Call and Webcast Today, November 25, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its 2025 fiscal year ended September 30, 2025. The Company is hosting a conference call today, November 25, 2025, at 4:30 p.m. ET to discuss the results. "The recent FDA approval of REDEMPLO, indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), is a transformational milestone for Arrowhead. REDEMPLO is the first and only FDA-approved siRNA medicine for people living with FCS and represents the first FDA-approval for a medicine leveraging Arrowhead's proprietary and differentiat
- REDEMPLO is the first and only FDA-approved medicine to be studied in patients with genetically confirmed and clinically diagnosed FCS - People living with FCS have extremely high triglyceride levels and a substantially higher risk of acute pancreatitis and related long-term complications, often resulting in a reduced quality of life - The FDA approval is based on positive results from the Phase 3 PALISADE study where REDEMPLO significantly reduced triglycerides from baseline and lowered the numerical incidence of acute pancreatitis compared to placebo - Arrowhead will host a conference call and webcast today at 1:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today anno
SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)
SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)